Join Dr. Robert Gould and Michael Girand as they discuss methods and applications for the use of EEG as a biomarker for sleep, substance use disorder and CNS disorders.

Electroencephalography (EEG) represents one of the primary methods to measure brain function in a non-invasive manner in humans and animals, thus providing a highly translational and powerful research tool to enhance basic academic as well as drug discovery research programs.

In this webinar sponsored by Data Sciences International (DSI), Dr. Robert Gould, Assistant Professor of Physiology and Pharmacology at Wake Forest School of Medicine, highlights several methods and applications for using EEG in freely moving rodents to enhance or complement research on CNS disorders. One well-known application of quantitative EEG (qEEG) is to examine different oscillatory patterns of brain function (e.g. diurnal rhythm, disease progression, pharmacological manipulations, etc.). In addition, Dr. Gould discusses how EEG can be used to study sleep architecture and arousal, addiction/substance use disorder, schizophrenia and drug discovery.

Michael Girand, Scientific Applications Manager at DSI, conveys a holistic approach when studying CNS-based applications and discusses how researchers can improve their study design and get more endpoints out of the animal model.

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.


To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.


Assistant Professor, Physiology and Pharmacology
Wake Forest School of Medicine

Dr. Robert Gould conducts translational pharmacology research pairing complex behavioral tasks with measures of brain function to aid our understanding of CNS disorders and develop novel pharmacotherapies. He has extensive experience examining pharmacological manipulations on behavior/brain function across preclinical models of addiction, depression, anxiety, schizophrenia and aging. Dr. Gould’s research currently involves investigating how altered brain function contributes to substance use disorder (SUD) and how normalizing aspects of aberrant brain function may facilitate successful addiction treatment. Modeling and attempting to reverse these substance-induced disorders, including sleep disturbances, represents a new treatment approach for SUD with direct application to human studies and clinical trials.

Scientific Applications Manager
Data Sciences International

Since joining DSI in 2007, Michael Girand’s responsibilities have included product management, technical and application support and sales. Managing the Scientific Applications team at DSI, he works with scientists to better understand the research environment and its challenges to take a collaborative approach to help scientists reach their research goals. Prior to working with DSI, he was a Research Scientist and Study Director at Warner-Lambert/Parke-Davis and Pfizer in Ann Arbor, MI for 12 years. While there, he had the opportunity to work in a variety of departments including Cardiovascular Pharmacology, General Toxicology, and Safety Pharmacology.

Production Partner

Data Sciences International

Data Sciences International (DSI) is the leader in preclinical physiological monitoring offering telemetry, instrumentation, software and services to help advance science. Industries served include: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, Medical Devices, Government, and Biotechnology.

Harvard Bioscience, Inc.

Harvard Bioscience is a global leader in the manufacturing and distribution of solutions to advance life science research. For over 110 years, we have served the changing needs of life scientists in over 100 countries. Our expanding portfolio of brands include instruments for organ and animal research, cell analysis, molecular biology, fluidics, and laboratory consumables.

Additional Content From Data Sciences International

Additional Content From Harvard Bioscience, Inc.

Related Content